CAD 0.77
(1.3%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | -100.0% |
2012 | 4.85 Million CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | -100.0% |
2005 | 783.45 Thousand CAD | 11.96% |
2004 | 699.75 Thousand CAD | 123.35% |
2003 | 313.3 Thousand CAD | 50.0% |
2002 | 208.86 Thousand CAD | 0.0% |
2001 | - CAD | -100.0% |
2000 | 310 Thousand CAD | 30999900.0% |
1999 | 1.00 CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 FY | - CAD | -100.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 FY | 4.85 Million CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2007 Q4 | - CAD | -100.0% |
2007 Q3 | 319.22 Thousand CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2006 FY | - CAD | -100.0% |
2006 Q3 | 320.45 Thousand CAD | -4.25% |
2006 Q2 | 334.68 Thousand CAD | 14.53% |
2006 Q4 | - CAD | -100.0% |
2006 Q1 | 292.22 Thousand CAD | 393.92% |
2005 Q1 | 244.65 Thousand CAD | 19.38% |
2005 Q2 | 167.97 Thousand CAD | -31.34% |
2005 FY | 783.45 Thousand CAD | 11.96% |
2005 Q3 | 245.03 Thousand CAD | 45.88% |
2005 Q4 | 59.16 Thousand CAD | -75.86% |
2004 Q1 | 117.35 Thousand CAD | -7.37% |
2004 Q4 | 204.94 Thousand CAD | 5.64% |
2004 Q2 | 183.46 Thousand CAD | 56.33% |
2004 Q3 | 194 Thousand CAD | 5.75% |
2004 FY | 699.75 Thousand CAD | 123.35% |
2003 Q1 | 43.17 Thousand CAD | -2.88% |
2003 FY | 313.3 Thousand CAD | 50.0% |
2003 Q4 | 126.69 Thousand CAD | 24.11% |
2003 Q3 | 102.08 Thousand CAD | 146.84% |
2003 Q2 | 41.35 Thousand CAD | -4.2% |
2002 Q1 | 57.18 Thousand CAD | 0.0% |
2002 FY | 208.86 Thousand CAD | 0.0% |
2002 Q4 | 44.45 Thousand CAD | -15.81% |
2002 Q3 | 52.79 Thousand CAD | -3.01% |
2002 Q2 | 54.43 Thousand CAD | -4.8% |
2001 FY | - CAD | -100.0% |
2001 Q2 | 1.00 CAD | 0.0% |
2001 Q3 | - CAD | -100.0% |
2001 Q1 | 1.00 CAD | -100.0% |
2001 Q4 | - CAD | 0.0% |
2000 Q1 | 1.00 CAD | 0.0% |
2000 Q2 | 1.00 CAD | 0.0% |
2000 Q3 | 1.00 CAD | 0.0% |
2000 Q4 | 309.99 Thousand CAD | 30999800.0% |
2000 FY | 310 Thousand CAD | 30999900.0% |
1999 FY | 1.00 CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Appili Therapeutics Inc. | 827.4 Thousand CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | - CAD | NaN% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 16.51 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | - CAD | NaN% |
Sernova Corp. | - CAD | NaN% |